ScreenerHero

IDIA Idorsia Ltd

SWX · CH · Healthcare · Biotechnology · idorsia.com
4.468CHF+0.22%Mkt Cap: 1.37B $P/E: —

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap1.37B USD
Enterprise Value2.74B USD
Revenue (TTM)227.93M USD
Gross Profit227.89M USD
Net Income (TTM)-127.48M USD
Revenue/Share0.82 CHF
Last Price4.468 CHF
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees424
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0363463438
Valuation
P/E (Trailing)—
P/E (Forward)80.59
PEG—
EV/EBITDA-17.27
EV/Revenue12.03
P/S6.01
P/B-0.98
EPS (TTM)-1.38
EPS (Forward)0.06
52W Range
2.79535% of range7.560
52W High7.560 CHF
52W Low2.795 CHF
Profitability
Gross Margin90.52%
Oper. Margin-68.86%
EBITDA Margin-69.66%
Profit Margin-50.64%
ROE9.82%
ROA-23.98%
Growth
Revenue Growth-26.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-174.88M USD
CapEx (TTM)15.77M USD
FCF Margin-17.62%
FCF Yield-2.93%
Net Debt1.40B USD
Net Debt/EBITDA-8.85
Balance Sheet
Debt/Equity-1.11
Current Ratio0.58
Quick Ratio0.36
Book Value/Sh-4.54 CHF
Cash/Share0.34 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 CHF
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 16, 2017
Pay DateOct 13, 2020
Analyst Consensus
Rating—
Target (Mean)5.333 CHF
Upside (mean)+19.4%
Target Range4.500 CHF – 6.000 CHF
4.500+19.4% to mean6.000
# Analysts3
Ownership
Shares Out.269.06M
Float151.51M
Insiders30.27%
Institutions32.76%
Technical
SMA 505.394 (-17.2%)
SMA 2004.553 (-1.9%)
Beta1.64
S&P 52W Chg14.58%
Avg Vol (30d)1.09M
Avg Vol (10d)1.04M
Technical Indicators
RSI (14)37.4
MACD-0.2481
MACD Signal-0.2634
MACD Hist.+0.0153
BB Upper5.243 CHF
BB Middle4.728 CHF
BB Lower4.213 CHF
BB Width21.78%
ATR (14)0.2199 CHF
Vol Ratio (20d)0.52x